Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Oncolytics Biotech Inc T.ONC

Alternate Symbol(s):  ONCY

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.


TSX:ONC - Post by User

Post by canadafanon Sep 04, 2023 5:53pm
364 Views
Post# 35619057

In about 16 hours, the Sept trading month will begin

In about 16 hours, the Sept trading month will begin

In about 16 hours the Sept trading month will begins.
We have been told , Sept will be/ is supposed to be the forwarded news on the PanCan trial.
For those new, or just coming back....the Pan Can trial is a phase 3 trial, for pancreatic cancer.
Featuring the extraordinary good results of a phase 2 trial with Roche & oncs pelareorep.
The results were good enough to grant fast track approval & the acceptance of PanCan.
it needs to be understood the acceptance of PanCan is huge!
They have in- place not only the physical infrastructure, meaning Multiple trial locations & patients lined up.
They also have the very important administrative & contact infrastructure with the FDA.
Pancan's only reason of existence is moving the standard of care for pancreatic cancer forward.
Beyond the PanCan, realm comes the bigger picture of a phase 3 trial for onc.
Yes, long awaited! 
They do need & have stated as such, a pharma partner to proceed.
Back to my opening statement. Roche, Pfizer & Incyte have the closest ties to Onc & Pela.
Being involved with multiple co- therapy trials, they have the inside track on trial data.
Roche?
Would seem to be top contender.
They do also have a larger focus with the Goblet trial.
The results & expected second half if this year. Meaning between now & Dec.
They mentioned " exciting presentations" as the ASCO symposium.
The deadline for standard abstracts is Sept 19th.
Negotiations? 

that being for a phase 3 partner. Roche could & most likely be waiting to see solid enough results.
ironically the longer the wait, assuming survivals are continuing, the more valuable Onc becomes.
So, it is possible the " final announcement " may be delayed, pending Goblet results.
Total takeover?
Could be announced, tomorrow, next month, next year or never.
From ONC's perspective:They are as close as ever in history to a phase 3 & market acceptance, for pancreatic cancer. Plus phase 3 ready MBc + on- going CAR-T trials. + a few other outlooks.
Assuming any one of those gets to approval, Onc becones a multi billion $$ company.
" don't want to undersell the company"
From an aquiring pharma;
Pelareorep needs solid enough proof that any investment can be worth the risk.
proof comes from studies.
Yes , they could buy early , at a discount. They carry the risk.
So until the doubts are proved out, Onc could be bought out however not at top price.
My likely scinario. A phase 3 partnership, followed by a complete buyout, once phase 3 starts to prove itself.
regards

 

<< Previous
Bullboard Posts
Next >>